Top Stories
OPKO had kept 4Kscore when it sold its BioReference oncology testing operations last year.
The two funds will invest in biopharmas, medical device and diagnostic developers, and tech-forward healthcare service providers.
The AI-focused drug discovery company sold 9.4 million shares at $16 apiece, the midpoint of its proposed range.
insitro will use its Virtual Human AI platform to identify novel targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies.
The tie-up comes a week after Danaher outlined plans to launch its first AI-powered lab in early 2027.
Conference News
Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device- or procedure-related serious adverse eventsPMA supplement submitted to the FDA to expand Genio’s in...
LAS VEGAS, NV, UNITED STATES, October 15, 2026 /EINPresswire.com/ -- Dr. Lucian Feraru, Chief Medical Officer of WoundScribe, today unveiled the company's AI-powered wound care app at SAWC Fall 2026, ...
New approach to PCR-free whole genome sequencing debuts at ASHG 2026 as Early Access beginsBoulder, Colorado, US, 15th October 2026 /Sciad Communications/ Watchmaker Genomics today announced the intro...
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® LungPresentation to address current challenges in pulmonary nodule management and to discuss pre...
NATICK, Mass., Oct. 15, 2026 /PRNewswire/ -- Pillar Biosciences today announced that ten scientific posters featuring their NGS technology will be presented, including a platform presentation at the 2...
